

40th Annual North American Cystic Fibrosis Conference

October 7-10, 2026
Atlanta, Georgia



Emory + Children's CF Center of Excellence (CF@LANTA) and
Center for CF & Airways Disease Research (CF-AIR)



Presentation Schedule and Information

Wednesday, October 7, 2026

Time / Location	Topic / Representative
8:00 am – 12:00 noon Location: Building A, Room 404-405	SPC01-- Addressing Loneliness by Fostering Social Connections that Spark Meaning in Life for People with CF (AM SESSION) Speaker: Christopher Drescher, PhD (Augusta University)
3:00 pm – 5:00 pm Location: Building B, Room 207-208	PEP-- Making PEP a Habit: Every Patient, Every Time Speaker: Brandi Middour-Oxler, DNP, CPNP (Emory University School of Medicine)

Thursday, October 8, 2026

Time / Location	Topic / Representative
7:45 am – 9:45 am Location: Building B, Room 312	W01-- Management of Infections & Inflammation in CF Presenter: Jacob D. Fairholm, MS (University of Georgia)
7:45 am – 9:45 am Location: Building B, Room 206	PGR-- Physicians Grand Rounds 1. Drug-Induced Liver Injury in a Woman Taking Elexacaftor/Tezacaftor/Ivacaftor for Fetal Cystic Fibrosis Therapy – Presented by Clement Ren Expert Discussant: Ryan Ford (Morehouse School of Medicine)
7:45 am – 9:45 am Location: Building B, Room 308	DG08-- Upholding Integrity: Ethics in Practice Speaker Ella Sorscher, MD, MBE and Community Speaker Nacida Marrero (Parent partner working with Children's Healthcare of Atlanta)
7:45 am – 9:45 am Location: Building B, Room 207-208	DG07-- Micronutrients, Metabolomics, & Modulators: What's Changing in CF Care Speaker: Thomas R. Ziegler, MD (Emory University School of Medicine)
9:00 am – 9:50 am Location: Building B, Halls 1 & 2 - Theater B	RFPT02-- Equity, Access, Cost, Health Equity Rapid-fire Chair: MacKenzie Wyatt, MD (Emory University/Children's Healthcare of Atlanta) 2. Endocrinologists' Experiences Caring for Gender-Diverse People with Cystic Fibrosis – Presented by Ryan Kann (Emory University School of Medicine)

10:15 am – 12:15 pm Location: Building B, Room 306	W08-- Impact of CFTR on Development & Aging Chair: Rabindra Tirouvanziam, PhD (Emory University)
10:15 am – 12:15 pm Location: Building B, Room 216	W09-- Aberrant Immunity in the Airway Speakers: Samantha Durfey, PhD (Emory University) and Diego Moncada Giraldo, PhD (Emory University)
10:15 am – 12:15 pm Location: Building B, Room 213-214	W11-- Psychosocial Research Showcase 2. Between Sickness and Wellness: Shifting Illness Identity in the Modulator Era – Presented by Ella Sorscher, MD, MBE
10:15 am – 12:15 pm Location: Building B, Room 206	W12-- Implementing & Improving CF Newborn Screening: Challenges, Solutions, & Lessons Chair: MacKenzie Wyatt, MD (Emory University/Children's Healthcare of Atlanta) 5. Variation in CF Newborn Screening Data Collection Impedes Effective Analysis of Outcomes – Presented by Rachel Linnemann, MD (Emory University/Children's Healthcare of Atlanta)
10:15 am – 12:15 pm Location: Building B, Room 402	W13-- Microbial Ecology & Polymicrobial Interactions of CF Airway 2. Antibiotic-Driven Resistance in Pseudomonas aeruginosa Follows Nonlinear, State-Dependent Dynamics in People with Cystic Fibrosis – Presented by Canan Karakoç, PhD (Georgia Tech)
10:15 am – 12:15 pm Location: Building A, Room 411-412	W10-- CF Clinical Trials Innovation, Impact, & What's New 2. Specialist Palliative Care Improves Quality of Life, Symptoms, and Advance Care Planning in Adults With CF: Results of the InSPIRe:CF Multisite Trial – Presented by Dio Kavalieratos, PhD, FAAHPM (Emory University)
12:30 pm – 2:00 pm Location: Building B, Halls 1 & 2	Junior Investigators: Top 10 Poster Judging Chair: Kathryn E. Oliver, PhD, MS, CPTS (Emory University School of Medicine) Poster Presenter: Srinivas Sowmiyanarayanan (Emory University)
1:00 pm – 5:00 pm Location: Building B, Room 310	SC01-- Managing GI & Liver Complications in CF: What Clinicians Need to Know Speaker: Vivek Shenoy, MD (Emory University/Children's Healthcare of Atlanta)
1:30 pm – 2:20 pm Location: Building B, Halls 1 & 2 - Theater B	RFPT04-- Clinical Markers of Response to Therapies Presenter: Advika Srinivasan (Georgia Tech and Emory University)
2:45 pm – 4:00 pm Location: Building B, Level 5 Thomas Murphy Ballroom	PL1-- Gene Editing at the Frontier: Advancing Precision Medicine & Delivery Science Speaker: James Dahlman, PhD (Emory University)
4:30 pm – 5:20 pm Location: Building B, Halls 1 & 2 - Theater B	RFPT06-- Novel Approaches to Infection Detection & Treatment 6. Bacterial Killing by Human CF Airway Neutrophils Is Modulated by the PD-1/SHP2 Axis and Ameliorated by Immune Checkpoint Inhibitor Therapy – Presented by Collin Leese-Thompson (Emory University)

4:30 pm – 6:30 pm
Location: Building A, Room
411-412

S10-- Body Composition in CF: What the Science Says & What We Do with It
1. State Of Research In CF Body Composition In Adults – **Presented by
Jessica Alvarez, PhD, RD (Emory University)**

4:30 pm – 6:30 pm
Location: Building B, Room
312

S04-- Battle of the Bots: AI in CF Care-Game Changer or Cause for Concern? A
Pro-Con Debate
**Chair: Dabney M. Eidson, RRT-NPS (Wellstar Children's Hospital of
Georgia)**

Poster Session – Friday, October 9, 2026, Odd Numbered Posters

12:15 pm–1:15 pm
Location: Building B, Halls 1
& 2

Poster 11: *Plasma from PwCF, and much less so ETI-treated PwCF, drives lung macrophage dysfunction.* A. Gewirtz, V. Ngo, S. Durfey, B. Kopp.

Poster 25: *Parallel and distinct signatures of adaptation in Pseudomonas aeruginosa chronic lung infections.* E. Mehlferber, I. Irby, S. Brown.

Poster 49: *Sublethal doses of the microbicidal compound hypothiocyanite convert methicillin-resistant Staphylococcus aureus to small colony variants.* J. Fairholm, B. Rada.

Poster 53: *Highly effective modulator therapies repair neutrophil's dysfunction in people with cystic fibrosis.* F. Robledo-Avila, R. Rascon, A. Montanez-Barragan, B. Kopp, S. Partida-Sanchez.

Poster 67: *Advancing precision antimicrobial strategies: Asobiotics for multidrug-resistant Pseudomonas aeruginosa.* D. Moustafa, C. Pybus, S. Banerjee, R. Koch, A. Nanayakkara, M. Sapkota, J. Goldberg, D. Greenberg.

Poster 75: *Mycobacterium abscessus evades immune responses in human primary macrophages.* G. Morales Artavia, G. Moschetti, L. Rizzello.

Poster 77: *Metabolism in flux: How CFTR loss disrupts mast cell mitochondrial function.* I. Miralda, K. Crotty, J. Moran, J. Chandler, B. Kopp.

Poster 85: *Determining Mycobacterium abscessus factors required for infection by therapeutic phage Itos.* S. Greenlund, G. Hatfull, K. Wetzel.

Poster 93: *Mycobacterium abscessus gene MAB_1350 is required for infection by some therapeutic phages.* O. Keita, C. Guerrero-Bustamante, N. McDonald, L. Serpa, R. Garlena, D. Russell, G. Hatfull, K. Wetzel.

Poster 95: *Two morphotypes, two strategies: Metabolic drivers of nitric oxide tolerance in Mycobacterium abscessus.* E. Aning, E. Evans, F. Diggle, M. Whiteley, B. Ross.

Poster 145: *Hyperglycemia contributes to modulation of neutrophil transmigration across bronchial epithelia.* G. Cui, J. Dudkin, K. Jones, J. Brown, R. Reed, R. Tirouvanziam, M. Koval, N. McCarty.

Poster 163: *Metabolite associations with post-tuberculosis lung disease suggest a common immunometabolic link with CF lung disease.* J. Lyles, A. Queiroz, G. Collins, M. Aldeco, P. Maenetje, D. Masilela, T. Ngwanto, R. Tirouvanziam, J. Chandler, G. Bisson, S. Auld.

- Poster 171:** *Insulin promotes barrier disruption in CF 16HBE cells under hyperglycemic conditions.* K. Jones, A. Vazquez Cegla, G. Cui, M. Koval, N. McCarty.
- Poster 179:** *Role of the mucin interactome on mucus biophysical characteristics.* M. Raihan, F. Fazelpour, A. Han, S. Danielsen, B. Button, M. Rubinstein, D. Hill.
- Poster 181:** *Bacterial killing by human CF airway neutrophils is modulated by the PD-1 / SHP2 axis and ameliorated by immune checkpoint inhibitor therapy.* D. Moncada Giraldo, C. Leese-Thompson, Z. Li, D. Luthra, R. Tirouvanziam.
- Poster 183:** *Elevated myeloperoxidase activity in non-CF bronchiectasis and shared metabolite profiles in CF and non-CF bronchiectasis.* A. Srinivasan, D. Moncada Giraldo, J. Lyles, Z. Li, G. Collins, A. Anwar, G. Silva, C. Driggers, A. Stecenko, C. Swenson, L. Guglani, R. Tirouvanziam, J. Chandler.
- Poster 193:** *Metabolomic signatures of pancreatic and hepatic fat in adults with and without cystic fibrosis: findings from the ORBIT-CF study.* A. Ramirez Tovar, L. Gonzalez Ramirez, S. Zaveri, C. Yang, S. Oh, A. Goss, D. Jones, V. Stallings, T. Daley, A. Stecenko, W. Hunt, P. Sharma, D. Walker, T. Ziegler, J. Alvarez.
- Poster 281:** *Inhibition of translation initiation as a unifying mechanism for rescue of CFTR nonsense variants.* A. Winters, E. Freestone, Y. Yang, Z. Traylor, E. Rintala, C. Foy, J. Jackson, L. Huang, M. Hastings, C. Hodges, K. Oliver.
- Poster 307:** *Activation of ΔR CFTR and relevance to nucleotide-based genetic Intervention.* D. Joshi, A. Rab, C. Barros, H. Davies, W. Tracy, E. Sorscher, J. Hong.
- Poster 311:** *Membrane cholesterol modulates CFTR function and structural dynamics.* J. Brown, G. Cui, K. Jones, N. McCarty.
- Poster 327:** *R-domain phosphorylation is altered in association with modulator treatment of W1282X CFTR.* J. Hong, D. Joshi, E. Sorscher, A. Rab.
- Poster 363:** *Between sickness and wellness: Shifting illness identity in the modulator era.* E. Sorscher, D. Kavalieratos, C. Hovater, K. Brus, B. Middour-Oxler, E. Dellon, J. Lower.
- Poster 411:** *Weekend sedentary time is associated with higher fasting and 60-minute plasma glucose in adults with cystic fibrosis.* V. Folli, S. Zaveri, L. Gonzalez Ramirez, R. Harris, W. Hunt, A. Stecenko, V. Stallings, T. Ziegler, J. Alvarez.
- Poster 469:** *Community support experiences of LGBTQIA+ people with cystic Fibrosis.* R. Salyer, L. Cevallos, S. Rashid, M. Lunn, J. Palla, G. Sequeira, A. Pranglely, A. Mitchell, O. Stransky, A. Alpern, V. Tangpritcha, J. Greenberg, R. Jain, N. Kahn, P. Community Partner Group, G. Sawicki, T. Kazmerski, K. Kidd.
- Poster 471:** *LGBTQIA+ people with cystic fibrosis: Experiences and preferences for care.* J. Palla, R. Salyer, L. Cevallos, G. Sawicki, T. Kazmerski, M. Lunn, R. Jain, V. Tangpritcha, J. Greenberg, O. Stransky.
- Poster 523:** *Handgrip strength as a potential marker of musculoskeletal health in children and young adults with cystic fibrosis.* N. Purohit, R. Joshi, E. Carrick,

R. Crandall, N. Wimmer, R. Harris, S. Purohit, K. McKie, D. Adair.

Poster 549: *CFTR modulators and the exocrine pancreas: An updated scoping Review.* A. Vargas, S. Li, R. Bass, A. Freeman, B. Kopp, L. Lara, P. Hart, M. Ramsey.

Poster 559: *Body composition and clinical implications in adults with CF: Base-line results of the STRONG-CF study.* M. Putman, A. Stein, H. Fonseca, Z. Reed, S. Freedman, S. Schwarzenberg, J. Sibayan, J. Clancy, J. Alvarez.

Poster 563: *Energy expenditure in clinically stable adults with cystic fibrosis is similar to healthy controls.* S. Zaveri, V. Folli, J. Tian, R. Weitnauer, J. Lei, L. Gonzalez Ramirez, S. Oh, A. Stecenko, W. Hunt, K. Easley, A. Goss, V. Stallings, T. Ziegler, J. Alvarez.

Poster 573: *Prevalence of pancreatic cysts among adults with cystic fibrosis: A retrospective review.* M. Ferrell, J. Bejjani, E. Park, S. Krishna, R. Bass, A. Freeman, B. Kopp, L. Lara, P. Hart, M. Ramsey.

Poster 599: *Non-CF bronchiectasis induces similar pathological programming airway neutrophil to CF in vivo and in vitro.* E. Browne, Z. Li, S. Padmanabhan, D. Moncada Giraldo, G. Silva, A. Anwar, C. Driggers, A. Stecenko, J. Chandler, C. Swenson, L. Guglani, R. Tirouvanziam.

Poster 601: *Characterizing CFTR-related disorder bronchiectasis and response to modulator therapy: A prospective multicenter registry cohort.* B. Zha, A. Brunton, D. Addrizzo-Harris, M. Devine, M. Johnson, G. Solomon, C. Richards, C. Swenson.

Poster 615: *Glycemic control in adult cystic fibrosis patients on elxacaftor/tezacaftor/ivacaftor therapy.* M. Guduru, H. Shah, R. Joshi, S. Purohit, C. Forseen, V. Taskar.

Poster 622: *Estimating the prevalence of hypogonadism symptoms in men with cystic fibrosis.* S. Sowmiyanarayanan, W. Hunt, V. Tangpricha.

Poster 667: *Predictors of successful sputum collection from adults with cystic fibrosis in the modulator era.* C. Driggers, K. Clemmer, D. Coker, K. Jones, W. Hunt, A. Stecenko, L. Guglani.

Poster 673: *Ancient DNA reveals selection on innate immune pathways and a potential genetic trade-off with cystic fibrosis in Europe after the Black Death.* S. Joseph, R. George, C. Leese-Thompson, D. Luthra, N. McCarty, C. LaRock, L. Waller, R. Tirouvanziam, J. Lindo.

Poster 717: *Elevating quality improvement skills among leaders in the Cystic Fibrosis Learning Network.* C. Enochs, O. Ries, L. Mitchell, K. Sabadosa.

1:15 pm–2:15 pm

Location: Building B, Halls 1 & 2

Poster 14: *Plasma from PwCF, and much less so ETI-treated PwCF, drives lung macrophage dysfunction.* A. Gewirtz, V. Ngo, S. Durfey, B. Kopp.

Poster 28: *Antibiotic-driven resistance in *Pseudomonas aeruginosa* follows nonlinear, state-dependent dynamics in people with cystic fibrosis.* C. Karakoç, S. Brown.

Poster 34: *Bile acids as potential immunomodulatory signals,* S. Durfey, J. Maaskant, J. Moran, I. Miralda, M. Shrestha, H. Ozuna, X. Ji, P. Dawson, J. Chandler, R. Tirouvanziam, B. Kopp.

Poster 56: *Mapping within-host genetic variation in *Pseudomonas aeruginosa* suppression of *Staphylococcus aureus* in a chronically co-infected cystic fibrosis airway.* A. Ramos Facio, J. Luu, S. Diggle, J. Goldberg, T. Read.

Poster 58: *Evaluating CFTR G551D transgenic ferrets as an animal model for *Mycobacteroides abscessus* lung infection in CF.* N. Gokanapudi, T. Gupta, K. Sakamoto, B. Ross, A. Stecenko, J. Engelhardt, F. Quinn, B. Rada.

Poster 70: *Defining the physiological differences between *Mycobacteroides abscessus* morphotypes in synthetic sputum media.* I. Abdullaeva, F. Diggle, B. Ross.

Poster 106: *Specialist palliative care improves quality of life, symptoms, and advance care planning in adults with CF: results of the InSPIRe: CF multisite trial.* D. Kavalieratos, J. Lowers, C. Hovater, K. Jeong, T. Wang, A. Stephenson, R. Arnold, J. Soodalter, J. Goggin, M. Bakitas, W. Hunt, K. Curseen, S. Barrett, J. Ailon, G. Solomon, L. Hanson, E. Dellon.

Poster 188: *Characterization of glucose and glutamine as metabolic regulators of energy production and redox homeostasis in CF neutrophils.* K. Crotty, J. Chandler.

Poster 224: *Basal cell-targeting PBATE nanoparticles enable nebulized mRNA delivery in mucus-rich lungs.* L. Rotolo, C. Monaco, Z. Sahin, M. Rivera, J. Luo, K. Liu, Y. Yuan, G. Singer, G. Cui, N. McCarty.

Poster 258: *Integrated computational and cell-based screens reveal new ribosomal inhibitors designed for rescue of CFTR nonsense and processing variants.* J. Jackson, D. Patel, J. White, K. Patel, A. Winters, E. Freestone, Y. Yang, C. Foye, Y. Du, K. Oliver.

Poster 336: *Elucidating mechanisms responsible for N1303K molecular phenotype and theratype variability.* A. Winters, C. Foye, J. Jackson, R. Mancinone, M. Hastings, L. Plate, J. Schleich, E. Sorscher, J. Hartman IV, K. Oliver.

Poster 338: *Elevated levels of glucose and arachidonic acid significantly reduce CFTR function and modulator sensitivity.* C. Foye, J. White, E. Freestone, G. Shirley, E. Rintala, G. Collins, A. Vazquez-Cegla, B. Kopp, J. Chandler, N. McCarty, J. Alvarez, T. Daley, K. Oliver.

Poster 358: *Identifying resource gaps and support needs among partners of*

individuals with cystic fibrosis: a mixed-methods needs assessment. M. Barker, R. Jernigan, Y. Imsand.

Poster 364: *ACT with CF Self-Help Toolkit: a standalone targeted mental health intervention for adults with cystic fibrosis.* M. Genecov, M. Renner, P. Smith, C. Drescher, K. Ingle, H. Bruschwein, C. O'Hayer.

Poster 372: *Anxiety and depression in adult cystic fibrosis patients receiving triple-combination modulator therapy –a single center perspective.* H. Shah, M. Guduru, R. Joshi, S. Purohit, C. Forseen, V. Taskar.

Poster 420: *Impact of elexacaftor/tezacaftor/ivacaftor on cardiopulmonary exercise responses measured by 1-minute sit-to-stand test in pediatric cystic fibrosis patients.* A. Pridgen, K. Krikorian, M. Starks, C. Bethune, M. House, G. Silva, L. Guglani.

Poster 424: *Survey of exercise testing and training in US cystic fibrosis care Centers.* N. Alotaibi, D. Lein, H. Yuen, S. Krick, R. Harris, J. Lowman.

Poster 466: *Area-level social determinants of health are associated with timeliness of evaluation or treatment in infants with a positive CF newborn screen in Georgia and Pennsylvania.* C. Ren, J. Faerber, R. Linnemann, S. McColley, M. McGarry, S. Mayne, L. Bennett, V. Tam, A. Sutaria, E. LaFon, M. Baker, P. Farrell.

Poster 470: *Endocrinologists' experiences caring for gender diverse people with cystic fibrosis.* R. Kann, R. Salyer, M. Lee, G. Sawicki, T. Kazmerski, M. Lunn, J. Palla, J. Greenberg, O. Stransky, A. Prangle, P. Community Partner Group, R. Jain, V. Tangpricha, K. Kidd.

Poster 498: *The cost efficacy of providing basic evidence-based cystic fibrosis care to at-risk children in Mexico City.* M. Tremblay, J. Lezana-Fernández, M. Reyes-Apodaca, S. Lee, K. Barrett.

Poster 522: *Iron deficiency contributes to sleep disorders in adults with cystic fibrosis on CFTR modulator therapy.* N. Purohit, R. Joshi, S. Lazaro, S. Purohit, C. Forseen, V. Taskar.

Poster 550: *Metabolic pathways associated with skeletal muscle health in adults with cystic fibrosis: An integrative network analysis.* L. Gonzalez Ramirez, M. Bellissimo, C. Driggers, R. Harris, W. Hunt, D. Jones, D. Liang, V. Stallings, A. Stecenko, J. Welsh, S. Zaveri, T. Ziegler, J. Alvarez.

Poster 564: *Comparison of body composition using bioelectrical impedance analysis versus dual energy X-ray absorptiometry in the STRONG-CF Study.* J. Alvarez, M. Putman, A. Stein, H. Fonseca, Z. Reed, S. Freedman, S. Schwarzenber, J. Sibaya, J. Clancy.

Poster 624: *Continuous glucose monitoring across the spectrum of glucose tolerance in CF: Baseline results of the STRONG-CF study.* M. Putman, J. Alvarez, H. Fonseca, Z. Reed, S. Freedman, S. Schwarzenberg, J. Sibayan, J. Clancy, A. Stein.

Poster 626: *Machine learning analytics of CGM quantifies dysglycemia scores that are strongly associated with defects in insulin secretion in cystic fibrosis.*

J. Song, J. Alvarez, A. Gent, S. Gillespie, R. Harris, C. Driggers, T. Daley, R. Kamaleswaran, A. Stecenko.

Poster 636: *Changing to a next generation sequencing based CF newborn screening algorithm in Pennsylvania improves time to evaluation and reduces disparities.* C. Ren, J. Faerber, R. Linnemann, S. McColley, M. McGarry, S. Mayne, N. Seshadri, A. Shenoy, L. Bennett, P. Farrell.

Poster 644: *Variation in CF newborn screening data collection impedes effective analysis of outcomes.* R. Linnemann, P. Farrell, C. Ren.

Poster 678: *Falling through the cracks: Healthcare utilization in CRMS.* M. Wyatt, A. Faino, A. Gupta, J. Cogen, M. McGarry.

Poster 690: *Integrating standardized health-related social needs screening (ELICIT+) in the adult CF clinic.* R. Joshi, D. Kelley, H. Stapp, S. Lazaro, M. Genualdi, K. Wetherington, V. Taskar, C. Forseen.

Poster 742: *Fecal elastase testing in children with cystic fibrosis on modulator therapy in a large pediatric center.* V. Shenoy, O. Ries, D. Batchelder, B. Baxter, C. Bethune, M. Cook, M. House, M. Martin, M. McKinnon, K. Patel, S. Pendley, M. Hazen, R. Linnemann.

Poster 774: *Early intervention with CFTR modulators can reverse exocrine pancreatic failure and achieve PERT independence: interim results from VNZ/TEZ/D-IVA open-label extension study in children aged ≥ 2 years.* A. Kasi.

Friday, October 9, 2026

Time / Location	Topic / Representative
7:45 am - 9:45 am Location: Building B, Room 207-208	DG19-- Technology in Research Chair: Rajeshree Joshi, MS (Augusta University)
7:45 am - 9:45 am Location: Building B, Room 310	DG18-- Social Worker/Mental Health Clinician Networking Chair: Emily Seibert, LPC, RPT, M.Ed. (Children's Healthcare of Atlanta)
7:45 am - 9:45 am Location: Building A, Room 404-405	DG15 -- Psychologist/Psychiatrist Networking Speaker: Christopher Drescher, PhD (Augusta University)
7:45 am - 9:45 am Location: Building B, Room 204	W15-- Pathogenesis of CF Airway Infection Chair: Brittany Ross, PhD (Georgia State University) 5. Two Morphotypes, Two Strategies: Metabolic Drivers of Nitric Oxide Tolerance in Mycobacterium abscessus – Presented by Ewurama Aning, MS (Georgia State University)
7:45 am - 9:45 am Location: Building A, Room 402-403	DG12-- Eating Right from the First Bite: Eating Behavior & Diet Quality Across the Lifespan Speaker: Caitlin Bascle, RDN, LD (Emory Healthcare)

9:00 am – 9:50 am Location: Building B, Halls 1 & 2 - Theater B	RFPT08-- Integrated Systems, Rapid Insights: Nutrition, GI, & Endocrine Care Chair: Maegan Cook MS, RD, CNSC, LD (Children's Healthcare of Atlanta)
9:00 am – 9:50 am Location: Building B, Halls 1 & 2 - Theater A	RFPT07-- Progress on Treatment of Noncoding & Nonsense Mutations 8. Inhibition of Translation Initiation as a Unifying Mechanism for Rescue of CFTR Nonsense Variants – Presented by Ashlyn Winters (Emory University)
10:15 am – 12:15 pm Location: Building B, Room 311	W30-- Reprogramming Epithelial & Immune Responses Through CFTR Modulation 1. Plasma from PwCF, and Much Less So ETI-Treated PwCF, Drives Lung Macrophage Dysfunction – Presented by Vu Ngo, PhD (Georgia State University)
10:15 am – 12:15 pm Location: Building B, Room 216	W19-- Epidemiology & Clinical Impact of Infection in CF 2. Parallel and Distinct Signatures of Adaptation in <i>Pseudomonas aeruginosa</i> Chronic Lung Infections – Presented by Elijah Mehlferber, PhD (Georgia Tech)
10:15 am – 12:15 pm Location: Building B, Room 204	W22-- Cellular Precision: Targeted Therapeutics Across Airway Cell Types 3. Basal Cell-Targeting PBATE Nanoparticles Enable Nebulized mRNA Delivery in Mucus-Rich Lungs – Presented by Laura Rotolo, PhD (Emory University)
10:15 am – 12:15 pm Location: Building B, Room 401	W28-- The Main Course: Best Nutrition Abstracts 2. Energy Expenditure in Clinically Stable Adults with Cystic Fibrosis Is Similar to Healthy Controls – Presented by Swati Zaveri, PhD (Emory University School of Medicine) 3. Comparison of Body Composition Using Bioelectrical Impedance Analysis Versus Dual-Energy X-Ray Absorptiometry in the STRONG-CF Study – Presented by Jessica Alvarez, PhD, RD (Emory University)
12:15 pm – 1:15 pm Location: Building B, Halls 1 & 2	Odd Numbered Posters in the Exhibit and Poster Hall (see poster listings above for details)
12:30 pm – 1:30 pm Location: Building B, Room 309	Basic Science Junior Investigator Competition Chair: Kathryn E. Oliver, PhD, MS, CPTS (Emory University School of Medicine)
1:15 pm – 2:15 pm Location: Building B, Halls 1 & 2	Even Numbered Posters in the Exhibit and Poster Hall (see poster listings above for details)
2:30 pm – 4:00 pm Location: Building B, Halls 1 & 2 - Theater A	TPS04-- Infection & Inflammation 8. Determining Mycobacterium abscessus Factors Required for Infection by Therapeutic Phage Itos – Presented by Sujay Greenlund, MS (Georgia State University) 10. Characterization of Glucose and Glutamine as Metabolic Regulators of Energy Production and Redox Homeostasis in CF Neutrophils – Presented by Kathryn Crotty (Emory University)

2:30 pm – 4:30 pm
Location: Building A, Room
411-412

S15-- Updates in Airway Delivery Platforms for Genetic Medicines
Speaker: James Dahlman, PhD (Emory University)

2:30 – 4:30 pm
Location: Building B, Room
401

S21-- Impact of Inflammation & Infection on CFTR Function & Rescue
1. Persistent Infection After CFTR Modulator Treatment Drives Ongoing Lung Inflammation – **Presented by Samantha Durfey, PhD (Emory University)**

2:30 – 4:30 pm
Location: Building B, Room
213-214

S13-- Starting Early: Prenatal CF Diagnosis & Counseling (From Screening to Delivery)
Chair: Rachel Linnemann, MD (Emory University/Children's Healthcare of Atlanta)

Saturday, October 10, 2026

Time / Location	Topic / Representative
7:45 am – 9:45 am Location: Building B, Room 311	W32-- Host Response to CF Airway Infections Chair: Samantha Durfey, PhD (Emory University)
8:00 am – 9:15 am Location: Building A, Room 406-407	C06-- Clinical Scene Investigation (CSI): CF PT & RT Complex Cases Chair: Amy Pridgen, PT (Children's Healthcare of Atlanta)
10:15 am – 12:15 pm Location: Building B, Room 401	W34-- Redefining the Routine: Integrating Innovative Treatments into Daily Care 5. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Cardiopulmonary Exercise Responses Measured by 1-Minute Sit-to-Stand Test in Pediatric Cystic Fibrosis Patients – Presented by Amy Pridgen, PT (Children's Healthcare of Atlanta)
10:15 am – 12:15 pm Location: Building B, Room 313-314	S30-- Movement is Medicine: Building Resilient Bodies in CF 3. Building Strength: Musculoskeletal Health and Exercise in CF – Presented by Jessica Alvarez, PhD, RD (Emory University) Chair: Ryan A. Harris, PhD, CEP, FACSM (Augusta University)
10:15 am – 12:15 pm Location: Building B, Room 216	S25-- One Organ Two Jobs: Understanding the Role of the Endocrine & Exocrine Pancreas in CF Chair: Vivek Shenoy, MD (Emory University/Children's Healthcare of Atlanta)
10:15 am – 12:15 pm Location: Building A, Room 411-412	W33-- Applying Quality Improvement Methods to Achieve Best Practices 1. Integrating Standardized Health-Related Social Needs Screening (ELICIT+) in the Adult CF Clinic – Presented by Rajeshree Joshi, MS (Augusta University) 4. Fecal Elastase Testing in Children with Cystic Fibrosis on Modulator Therapy in a Large Pediatric Center – Presented by Olivia Reis (Children's Healthcare of Atlanta)